Reduction or Discontinuation of CNI's With Conversion to Everolimus-Based Immunosuppresion

Kidney Diseases Clinical Trial

Official title:

Reduction or Discontinuation of Calcineurine Inhibitors With Conversion to Everolimus-Based Immunosuppresion to Alleviate Chronic Allograft Nephropathy (CAN) in Kidney Transplant Recipients: A Prospective Randomized Study

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT00443508
• Other study ID #: CRAD001AIL01
• Status: Recruiting
• Phase: Phase 4
• First received: March 4, 2007
• Last updated: March 5, 2007
• Start date: February 2007
• Est. completion date: February 2010

Study information

• Verified date: September 2005
• Source: Rabin Medical Center
• Contact: Eytan Mor, Prof
• Phone: 00973 3 9376528
• Email: emor[@]clalit.org.il
• Is FDA regulated: No
• Health authority: Israel: Israeli Health Ministry Pharmaceutical Administration
• Study type: Interventional

Clinical Trial Summary

This study is design to compare two different strategies aiming to lessen the degree of the ongoing process of allograft injury either by removing tacrolimus from the maintenance immunosuppressive protocol or by reducing tacrolimus dose.

The primary goal is to assess the change in renal function at 6 and 12 months after conversion using creatinine levels and calculated creatinine clearance.

The study will include two groups: The study group of 30 patients and a matched control group with creatinine levels at similar range.

Description:

This study is design to compare two different strategies aiming to lessen the degree of the ongoing process of allograft injury either by removing tacrolimus from the maintenance immunosuppressive protocol or by reducing tacrolimus dose.

The primary goal is to assess the change in renal function at 6 and 12 months after conversion using creatinine levels and calculated creatinine clearance.

The study will include two groups: The study group of 30 patients and a matched control group with creatinine levels at similar range.

Patients will undergo the following baseline studies:

1. Doppler ultrasound to exclude any mechanical or a vascular problem.

2. A kidney biopsy to define the histological changes (degree of interstitial fibrosis, tubular and glomerular changes). The biopsies will be stained also for C4D and for fibrinogenic markers (TGF-beta, and collagen).

3. A 24-hour urine protein excretion and creatinine clearance

4. Echocardiography study

5. Carotid Ultrasound

The following parameters will be monitored every clinic visit throughout the study period:

1. SMA-12 including creatinine levels.

2. A complete blood count.

3. Cholesterol, HDL-cholesterol and triglyceride levels.

4. Blood pressure measurements (X2)

5. The number of blood pressure medications.

6. Cholesterol lowering medication requirement

7. Urine protein excretion (quantitative spot-test )

8. Protein amount in the urine

Study end points:

The data will be evaluated based on an intention to treat analysis and the following parameters will be compared between the two groups:

1. Creatinine levels and calculated creatinine clearance

2. Spot urine for Cr./protein ratio

3. 24-hr. protein excretion

4. Change in peak diastolic and mean arterial blood pressure

5. The number and dosage of blood pressure medications

6. Cholesterol, HDL and triglyceride levels

7. Proportion of patients on cholesterol lowering agents

8. Number and severity of biopsy proven acute rejection episodes

9. Incidence of biopsy proven chronic rejection. (depends on per protocol biopsy at end of study)

10. Patient and graft survival

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 60
• Est. completion date: February 2010
• Accepts healthy volunteers: No
• Gender: Male
• Age group: N/A and older

Eligibility

Inclusion Criteria:

• Patients on CNI FK < 5 ng/m"l with MPA / Imuran with or without steroids

• Renal impairment GFR between 30 - 70 m"l/minute/

• Patient who signed Informed consent

• Patient with no contraindication to renal biopsy

• Women who are not pregnant and will use contraception

Exclusion Criteria:

• Proteinuria > 100 m"g/mmol Creatinine

• Acute rejection during 3 months before screening

• WBC < 2500, plt < 50,000,

• Nephropathy due to polyoma virus

• Patients on other investigational drugs

• Patients on rapamycin

• Patients with HIV or other systemic infection

• Inability to comply with protocol requirements

• Active or history of malignancy

Study Design

Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment

Related Conditions & MeSH terms

• Kidney Diseases

Intervention

Drug:
• adding Certican to therapy

• reducing Tacrolimus

Locations

Country	Name	City	State
Israel	Transplantation department, rabin Medical Center	Petach Tikva

Sponsors (2)

Lead Sponsor	Collaborator
Rabin Medical Center	Novartis

Country where clinical trial is conducted

Israel, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	The primary goal is to assess the change in renal function
Primary	at 6 and 12 months after conversion using creatinine levels
Primary	and calculated creatinine clearance.
Secondary	The secondary aim is to assess changes in cardiovascular risks at
Secondary	12 months after conversion (glucose control., cholesterol and
Secondary	triglyceride levels and hypertension control), incidence of
Secondary	acute and chronic rejection and graft and patient survival rates.